INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME
申请人:Infinity Pharmaceuticals, Inc.
公开号:US20150344503A1
公开(公告)日:2015-12-03
The present invention provides compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III).
Methods of preparing compounds encompassed by the formulae (I), (II) or (III) are also provided. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
Boronic acids and esters as inhibitors of fatty acid amide hydrolase
申请人:Infinity Pharmaceuticals, Inc.
公开号:EP2399584A1
公开(公告)日:2011-12-28
The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE
申请人:Infinity Pharmaceuticals, Inc.
公开号:EP2073816B1
公开(公告)日:2011-09-14
INHIBITORS OF FATTY ACID AMIDE HYDROLASE
申请人:Adams Julian
公开号:US20090099131A1
公开(公告)日:2009-04-16
The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III).
The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.